Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Feb;47(2):257-259.
doi: 10.1111/jcpt.13504. Epub 2021 Jul 28.

Chronic oxcarbazepine intoxication in a patient with primary antiphospholipid syndrome on maintenance haemodialysis

Ahmet Burak Dirim  1 , Safak Mirioglu  1 , Nilufer Yesilot  2 , Emin Oguz  3 , Halil Yazici  1 , Murat Inanc  3 , Bahar Artim-Esen  3
Affiliations
Case Reports

Chronic oxcarbazepine intoxication in a patient with primary antiphospholipid syndrome on maintenance haemodialysis

Ahmet Burak Dirim et al. J Clin Pharm Ther. 2022 Feb.

Abstract

What is known and objective: Oxcarbazepine (OXC) is an antiepileptic drug. Patients suffering from chronic kidney disease with an estimated glomerular filtration rate below 30 ml/min/1.73 m2 require dose adjustments for OXC.

Case summary: A 31-year-old man was admitted with a history of diplopia, ataxia and dizziness attacks that had disappeared after a regular haemodialysis sessions for three months. Medical history was remarkable for primary antiphospholipid syndrome (APS). However, no signs of new-onset APS-related neurological involvement were present. Then, it was revealed that the patient had been using 2400 mg/day of OXC for four months, despite the prescription of half of this dose. Serum OXC level was 50 mcg/ml (reference: 3-35 mcg/ml) before a regular haemodialysis session. All symptoms disappeared in a few days after reducing to 1200 mg/day and never recurred.

What is new and conclusion: We reported a chronic OXC intoxication in a patient on maintenance haemodialysis. To the best of our knowledge, it is the first chronic OXC intoxication case in the literature. It could be related to episodic removal of OXC and its metabolites via haemodialysis. Consequently, dose modification of drugs is a pivotal point in haemodialysis patients. Chronic drug intoxications must be kept in mind in haemodialysis patients with unexplained symptoms.

Keywords: haemodialysis; intoxication; oxcarbazepine.

PubMed Disclaimer

References

REFERENCES

    1. Phelps SJ, Wheeles JW. Oxcarbazepine: a brief review. J Pediatr Pharmacol Ther. 2005;10:248-253.
    1. Beydoun A. Safety and efficacy of oxcarbazepine: results of randomized, double-Blind trials. Pharmacotherapy. 2000;20:152S-158S.
    1. Musso CG, Vilas M, Aparicio C, et al. Oxcarbazepine induced hyponatremia: A potential explanation of its physiopathology. Electron J Biomed. 2009;1:32-35.
    1. Karasu E, Baktir AO. Three Types of Atrioventricular Block Induced by Oxcarbazepine in a Young Adult. Klin Psikofarmakol B. 2013;23(1):84-88.
    1. Orozco B, Garlich F, Hick J. Oxcarbazepine Overdose Causing an Accelerated Junctional Rhythm with Atrioventricular Dissociation. Clin Toxicol. 2010;48:657.

Publication types

LinkOut - more resources